Pill Connect company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Series A | Alive

Total Raised


Last Raised

$670K | 2 yrs ago

About Pill Connect

Pill Connect is a medical device company which creates and builds propriety medication adherence solutions. The company has developed two wireless devices which transform static medicine dispensing products into active systems that promote patient adherence, improve safety and aid patient recovery.

Pill Connect Headquarter Location

Unit 28 Greenheys Business Centre Pencroft Way

Manchester, England, M15 6JJ,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pill Connect

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pill Connect is included in 5 Expert Collections, including Pharma Supply Chain.


Pharma Supply Chain

1,258 items


Medical Devices

8,082 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Digital Health

12,800 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Biopharma Tech

401 items


Health IT

7,900 items

Pill Connect Patents

Pill Connect has filed 2 patents.

The 3 most popular patent topics include:

  • Clinical research
  • Dietary supplements
  • Health informatics
patents chart

Application Date

Grant Date


Related Topics




Dietary supplements, Clinical research, Health informatics, Pharmaceutical industry, Medical terminology


Application Date


Grant Date



Related Topics

Dietary supplements, Clinical research, Health informatics, Pharmaceutical industry, Medical terminology



Latest Pill Connect News

AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence

Feb 4, 2021

AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence Integrated Digital Solutions Enhance Solid Oral Dose Medication Adherence Measurement Liege, February 2nd 2021 – Belgium-based AARDEX Group, the world leader in medication adherence solutions, today announced a strategic partnership with Pill Connect Ltd, an English company specializing in the design, development and manufacture of innovative medical devices for dispensing solid oral dose medication. The collaboration will link AARDEX’s proprietary Medication Event Monitoring System (MEMS®) with Pill Connect’s add-on solutions for drug delivery devices. The combined system has significant potential to radically influence patients’ adherence performance. Through this strategic alliance, AARDEX will reinforce its comprehensive portfolio of smart solutions and connected devices available to effectively measure and manage medication adherence for patients and healthcare providers. There are significant benefits to be gained from ecosystems that seamlessly measure and analyze patient adherence to medications in clinical trials. The successful management of this is supported by research settings and professional healthcare systems. The first initiative will integrate Pill Connect’s smart dosing system with AARDEX’s MEMS Adherence Software (MEMS AS®) for medicines delivered in solid oral dose form. The collaboration will start in academic research, followed by drug development clinical trials, and then extended to commercialized drugs and real-life conditions. David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, commented, “Smart packaging is one of the most reliable ways to accurately measure, describe, manage and influence patient adherence in relation to medication. It highly correlates with patient behaviour, making the results highly valuable. It is a proven way to minimize risk while being a seamless experience for patients. The objective is to support an unbiased and precise measure of medication adherence in key therapy areas, not only for commercialized drugs and real-life conditions, but also clinical trials and drug efficacy. This partnership will also be pivotal in enhancing the impact of academic research findings.”   James Burnstone, CEO of Pill Connect Ltd commented, “Managing patient compliance can make the difference between failed and successful clinical trials. The combination of Pill Connect’s smart dosing systems with the AARDEX MEMS AS® system ensures the precise capture and analysis of data for clinical trials and adherence monitoring. We are delighted to be collaborating to bring these solutions to our customers. For clinical trials, the integration of this kind of tool will improve the speed and accuracy of medication adherence assessment and intervention efficacy and potentially decrease the rate of unnecessary mediation, bolstering success at every level.” AARDEX is passionate about continuously innovating data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Evidence-based digital adherence monitoring systems can help improve clinical results and conclusions, maximizing the chances of success in clinical trials. Sponsors can improve drug efficacy by managing patient adherence to the study medications and pharma companies can reliably and seamlessly monitor and address patient medication adherence, minimizing risks of trial failure or costly adjustments. About AARDEX Group                                                                                                         AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. With operations in Belgium, Switzerland and the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. AARDEX’ vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. About Pill Connect Ltd Pill Connect Ltd is a health technology company based in Manchester, UK developing smart solutions to improve patient care. Pill Connect’s smart dispensing system which aims to improve and monitor patient adherence, concluded its first clinical trials in 2019. For Media Enquiries:  Sophie Beattie

  • When was Pill Connect founded?

    Pill Connect was founded in 2013.

  • Where is Pill Connect's headquarters?

    Pill Connect's headquarters is located at Unit 28 Greenheys Business Centre Pencroft Way, Manchester.

  • What is Pill Connect's latest funding round?

    Pill Connect's latest funding round is Series A.

  • How much did Pill Connect raise?

    Pill Connect raised a total of $670K.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.